Black Book Recaps 2025 Research Announcements and Client‑Rated Honors; Reaffirms Vendor‑Agnostic, Independently Validated Intelligence and 2026 Commitments 
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency...
OneMedNet Reports Over 25% Expansion of iRWD™ Network, Encompassing Clinical Data alongside Aggregate Health Economics and Social Determinant Insights from 5 Billion Administrative Records, Fueling Growth in AI-Powered Healthcare Data
Over 1,750 provider sites and access to 136 million clinical exams positions OneMedNet for accelerated revenue and market penetrationMINNEAPOLIS, Aug....
Full Alliance Group Launches QUBEE HIVE HOLDINGS to Advance Global Web3 Financial Infrastructure
Strategic Infrastructure Development Positions Company for Global Fintech ExpansionTAMPA, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group, Inc....
RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors
ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to...
MaxCyte Signs Platform License Agreement with Adicet Bio
MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs...
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the...
Xenon to Report Q2 2025 Financial Results on August 11, 2025
VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company...
Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in...
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the...
LifeMD to Participate in the Canaccord Genuity 45th Annual Growth Conference
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services,...
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and...
Connect Appoints James Zanewicz as Chief Executive Officer to Shape the Next Chapter of Innovation Growth
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Connect, the premier nonprofit organization in the San Diego innovation ecosystem established...
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency Approximately 22% of patients reached 100%...
Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on...
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk...
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
VOCAL, an open-label active-controlled study, is being conducted at DaVita dialysis clinics to evaluate benefits of treating patients with Vafseo...
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31,...
Glass House Brands Provides Updates to Recent Events
LONG BEACH, Calif. and TORONTO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”)...
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
The MOU intends to combine proprietary mRNA vaccine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus.Philadelphia,...
CAS SciFinder integrates transformative new science-smart AI capabilities to enhance R&D efficiency and boost innovation
Pioneering solution provides scientists with actionable answers faster to accelerate scientific discovery COLUMBUS, Ohio, Aug. 4, 2025 /PRNewswire/ -- CAS,...